The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Current treatment options for vulvovaginal candidiasis caused by azole-resistant Candida species
Abstract
INTRODUCTION: Clinicians are increasingly challenged by patients with refractory vulvovaginal candidiasis (VVC) caused by azole-resistant Candida species. Fluconazole resistant C.albicans is a growing and perplexing problem following years of indiscriminate drug prescription and unnecessary drug exposure and for which there are few therapeutic alternatives. Regrettably, although the azole class of drugs has expanded, new classes of antifungal drugs have not been forthcoming, limiting effective treatment options in patients with azole resistant Candida vaginitis. AREAS COVERED: This review covers published data on epidemiology, pathophysiology and treatment options for women with azole-resistant refractory VVC. EXPERT OPINION: Fluconazole resistant C.albicans adds to the challenge of azole resistant non-albicans Candida spp. Both issues follow years of indiscriminate drug prescription and unnecessary fluconazole exposure. Although an understanding of azole resistance in yeast has been established, this knowledge has not translated into useful therapeutic advantage. Treatment options for such women with refractory symptoms are extremely limited. New therapeutic options and strategies are urgently needed to meet this challenge of azole drug resistance.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recurrence can also result from developed resistance to antifungal treatment, usually due to prolonged or repeated use of a single agent. 11”
From Clinical challenges in diagnosis and treatment of recurrent vulvovaginal candidiasis (2022) · cites this paper as [11]
In the citing paper
“Although breakthrough infections are still relatively rare (usually < 5% of patients), in vitro susceptibility testing can be useful in selecting subsequent treatment.11,18”
From Clinical challenges in diagnosis and treatment of recurrent vulvovaginal candidiasis (2022) · cites this paper as [11]
In the citing paper
“Development of azole-resistant infection may be suspected in women who do not respond to standard treatment regimens or who experience breakthrough symptoms despite compliant long-term fluconazole maintenance therapy. 11”
From Clinical challenges in diagnosis and treatment of recurrent vulvovaginal candidiasis (2022) · cites this paper as [11]
In the citing paper
“Treating azole-resistant vaginitis constitutes a major clinical challenge for providers, given the current paucity of alternative antimycotic agents. 11”
From Clinical challenges in diagnosis and treatment of recurrent vulvovaginal candidiasis (2022) · cites this paper as [11]
In the citing paper
“in vitro susceptibility testing can be useful in selecting subsequent treatment.11,18”
From Clinical challenges in diagnosis and treatment of recurrent vulvovaginal candidiasis (2022) · cites this paper as [11]
In the citing paper
“In addition, non-albicans Candida species are frequently dose-dependent susceptible or resistant to fluconazole and other azoles, and their prevalence is rising.”
From Management of recurrent vulvovaginal candidosis: Narrative review of the literature and European expert panel opinion (2022) · cites this paper as Sobel and Sobel, 2018
In the citing paper
“A long-term prophylactic maintenance regimen with antifungals is often necessary.”
From Management of recurrent vulvovaginal candidosis: Narrative review of the literature and European expert panel opinion (2022) · cites this paper as Sobel and Sobel, 2018
In the citing paper
“Available therapeutic options to treat such fluconazole-resistant C. albicans and low susceptibility non-albicans strains are limited.”
From Management of recurrent vulvovaginal candidosis: Narrative review of the literature and European expert panel opinion (2022) · cites this paper as Sobel and Sobel, 2018
In the citing paper
“Many fluconazole-resistant C. albicans strains are also cross-resistant to other azole drugs available for treating VVC.”
From Management of recurrent vulvovaginal candidosis: Narrative review of the literature and European expert panel opinion (2022) · cites this paper as Sobel and Sobel, 2018
In the citing paper
“Fluconazole-resistant C. albicans vaginitis usually represents less than 5% of isolates obtained from women with RVVC (Sobel and Sobel, 2018; Collins et al., 2020).”
From Management of recurrent vulvovaginal candidosis: Narrative review of the literature and European expert panel opinion (2022) · cites this paper as Sobel and Sobel, 2018
In the citing paper
“Treatment with first- or second-generation azoles for C glabrata infection is usually unsuccessful, and local nystatin, ciclopiroxolamine, or boric acid is recommended (Sobel and Sobel, 2018).”
From Management of recurrent vulvovaginal candidosis: Narrative review of the literature and European expert panel opinion (2022) · cites this paper as Sobel and Sobel, 2018
Citations
Cites
J Antimicrob Chemother 1994; 33: 350–351
O’Shaughnessy, E. M., & DAS, S. S. (1994) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/33.2.350 · Cited by 3,758
Pappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191
Sobel, J. D. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60917-9 · Cited by 1,270
Self-citationResistance of Candida species to fluconazole
Rex, J. H., Rinaldi, M. G., & Pfaller, M. A. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.1.1 · Cited by 880
Multidrug-Resistant Candida: Epidemiology, Molecular Mechanisms, and Treatment
Arendrup, M. C., & Patterson, T. F. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix131 · Cited by 707
Global burden of recurrent vulvovaginal candidiasis: a systematic review
Denning, D. W., Kneale, M., Sobel, J. D., & Rautemaa-Richardson, R. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30103-8 · Cited by 639
Self-citationWhite, T. C. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.7.1482 · Cited by 612
Sanglard, D., Ischer, F., Monod, M., & Bille, J. (1997) · Microbiology · doi:10.1099/00221287-143-2-405 · Cited by 587
Recurrent vulvovaginal candidiasis
Sobel, J. D. (2016) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2015.06.067 · Cited by 502
Self-citationMaintenance Fluconazole Therapy for Recurrent Vulvovaginal Candidiasis
Sobel, J. D., Wiesenfeld, H. C., Martens, M., Danna, P., Hooton, T. M., Rompalo, A., Sperling, M., Livengood, C., Horowitz, B., Von Thron, J., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033114 · Cited by 487
Self-citation
Research works printed but not linked: 8
- Denning D, 2018, Lancet Infect Dis
- Kalaiarasan K, 2017, J Clin Diagn Res, 11, DC06
- Pappas PG, 2016, Clin Infect Dis, 62(4):e1-50
- Patel PK, 2012, AIDS Res Treat, 2012, 262471
- Clark-Ordóñez I, 2017, Med Mycol
- Sanglard D, 2016, Front Med (Lausanne), 15, 11
- De Seta F, 2009, J Antimicrob Chemother
- White DJ, 1993, Genitourin Med, 69, 112
Cited by
Sorted by citations
Items 101–168 of 168
Nanoformulation of A Novel Potent Ebselen Analog for Treatment of Vulvovaginal Candidiasis
Liang, X., Menon, S., Vartak, R., Gaida, R., Wojaczyńska, E., Patel, K. R., & Billack, B. (2023) · Nanomedicine · doi:10.2217/nnm-2022-0323 · Cited by 4
Proposal for a microcosm biofilm model for the study of vulvovaginal candidiasis
Cordeiro, R. D. A., de Andrade, A. R. C., Portela, F. V. M., Pereira, L. M. G., Moura, S. G. B., Sampaio, M. D., Pereira, E. M. A., Guedes, G. M. D. M., Bandeira, S. P., de Lima-Neto, R. G., et al. (2020) · Biofouling · doi:10.1080/08927014.2020.1785435 · Cited by 5
Mohana, P., Singh, A., Rashid, F., Singh, S., Kaur, K., Rana, R., Bedi, P. M. S., Bedi, N., Kaur, R., & Arora, S. (2024) · The Journal of Microbiology · doi:10.1007/s12275-024-00174-5 · Cited by 4
(2022) · PubMed Central · doi:10.19852/j.cnki.jtcm.2022.04.001 · Cited by 4
Klesiewicz, K., Mrowiec, P., Kania, K., Skiba‐Kurek, I., Białecka, J., Namysł, M., & Małek, M. (2023) · Polish Journal of Microbiology · doi:10.33073/pjm-2023-011 · Cited by 4
Drug-loaded electrospun nanofiber for Vulvovaginal candidiasis: A systematic literature review
Vidyadhari, A., Singh, A. K., Ralli, T., Parvez, S., & Kohli, K. (2023) · Clinical Epidemiology and Global Health · doi:10.1016/j.cegh.2023.101420 · Cited by 4
Liang, X., Pacuła‐Miszewska, A. J., Obieziurska‐Fabisiak, M., Vartak, R., Mao, G., Patel, K. R., Fedosova, N. U., Ścianowski, J., & Billack, B. (2023) · Molecules · doi:10.3390/molecules28217377 · Cited by 4
Kpongbo, E. A., Djohan, V., Ira-Bonouman, A., Vanga-Bosson, A. H., Kassi, K. F., Abibatou, K., Valérie, A. B.-T., Sébastien, A. M., Christiane, P. K.-B., Hervé, M. E. I., et al. (2018) · Journal of Yeast and Fungal Research · doi:10.5897/jyfr2018.0185 · Cited by 4
Xue, L., Yang, L., Fu, X.-Z., Feng, W.-L., Yang, J., Ma, Y., & Xi, Z. (2025) · Biochemical and Biophysical Research Communications - BBRC · doi:10.1016/j.bbrc.2025.152147 · Cited by 5
Strydom, M. B., Nelson, T. M., Khan, S. A., Walpola, R. L., Ware, R. S., & Tiralongo, E. (2024) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-024-04999-1 · Cited by 5
Akdağ, D., Pullukçu, H., Yamazhan, T., Metin, D. Y., Sıpahı, O. R., Ener, B., & Tasbakan, M. I. (2020) · Journal of Obstetrics and Gynaecology · doi:10.1080/01443615.2020.1732893 · Cited by 3
Bignoumba, M., Onanga, R., Kumulungui, B., Kassa, R. F. K., Mouanga-Ndzime, Y., Moghoa, K. M., Stubbe, D., & Becker, P. (2022) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2022.101354 · Cited by 3
Rashidi, M., Bazı, A., Ahmadzadeh, A., Romeo, O., Rezaei‐Matehkolaei, A., Abastabar, M., Haghani, I., & Mirzaei, S. (2023) · Journal of Applied Microbiology · doi:10.1093/jambio/lxad201 · Cited by 3
Porto, R., & Porto, V. A. (2023) · Pharmaceutical Patent Analyst · doi:10.4155/ppa-2023-0021 · Cited by 4
Nikoomanesh, F., Falahati, M., dos Santos, A. L. S., Rodrigues, C. F., Mohammadi, S. R., Rafiee, M., Černáková, L., & Roudbary, M. (2023) · Preprints.org · doi:10.20944/preprints202301.0087.v1 · Cited by 3
Lajarin-Reinares, M., Naveira-Souto, I., Mallandrich, M., Suñer-Carbó, J., Llagostera Casas, M., Calvo, M. A., & Fernandez-Campos, F. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15051436 · Cited by 2
Zhang, H., Li, C., Wu, H., Li, Z., Wu, D., Shao, J., Wang, T., & Wang, C. (2024) · Fitoterapia · doi:10.1016/j.fitote.2024.106250 · Cited by 2
Li, Z., Wu, H., Li, C., Wang, Y., Shao, J., Wu, D., Wang, T., & Wang, C. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.119292 · Cited by 2
Bahmaee, F., Khodavandi, P., Khodavandi, A., & Alizadeh, F. (2025) · Inorganic Chemistry Communications · doi:10.1016/j.inoche.2025.115093 · Cited by 2
Antifungal activity of amniotic fluid against different Candida species
Maraki, S., Stafylaki, D., Karageorgos, S. A., Koutroumpakis, F., Hamilos, G., Makrigiannakis, A., & Samonis, G. (2021) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2021.02.002 · Cited by 2
Generalidades de la candidiasis vulvovaginal
Jiménez, J. C., Garro, Á. R. G., & Trabado, S. J. T. (2023) · Revista Medica Sinergia · doi:10.31434/rms.v8i3.924 · Cited by 2
SPECIES DISTRIBUTION AND ANTIFUNGAL SUSCEPTIBILITY OF VAGINAL CANDIDA ISOLATES
Hitkova, H. Y., & Georgieva, D. (2024) · PROBLEMS of Infectious and Parasitic Diseases · doi:10.58395/2enj2697 · Cited by 2
Nicolodi, M. A. D., & Danielli, G. (2023) · RECIMA21 - Revista Científica Multidisciplinar · doi:10.47820/recima21.v4i3.2867 · Cited by 2
Nanomedicine for the Treatment of Vaginal Candidiasis
Vartak, R., Menon, S., Patki, M., Liang, X., Billack, B., & Patel, K. R. (2023) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-031-39020-3_5 · Cited by 2
Alhashem, R., & Hosseini, S. S. (2024) · شهباز. · doi:10.61186/mlj.18.1.34 · Cited by 1
Volkova, O. N., Amel’chenko, E. V., Makeeva, O. V., Tolmachev, S. A., Lesovaya, E. A., Zacharia, L. C., & Dikovskiy, A. V. (2025) · BMC Women s Health · doi:10.1186/s12905-025-03616-3 · Cited by 1
Dambly, J. M., Dutra, K. J., Sobel, R., Stephens, R. W., Dorsey, L. B., Romano, C. M., & Nyirjesy, P. (2025) · Journal of Lower Genital Tract Disease · doi:10.1097/lgt.0000000000000924 · Cited by 1
Self-citationSong, J., Cheng, X., Gao, J., Liang, Z., Han, X., & Zhao, H. (2025) · Natural Product Research · doi:10.1080/14786419.2025.2583348 · Cited by 1
Cosentino, L. A., Petrina, M. A. B., Zamborsky, T., Beamer, M. A., Macio, I. S., Meyn, L. A., Bunge, K. E., & Hillier, S. L. (2026) · Microbiology Spectrum · doi:10.1128/spectrum.02353-25 · Cited by 1
Kalkan, Ü., Yassa, M., Sandal, K., Tekin, A. B., KILINÇ, C., Gülümser, Ç., & Tuğ, N. (2021) · Journal of Experimental and Clinical Medicine · doi:10.52142/omujecm.38.4.11 · Cited by 1
Pérez-Llantada, J. G., Masero-Casasola, A. R., Lázaro-Carrasco, J., Carballo, M. J., Ridocci, F., Sosa, M., González, M., Azumendi, P., Palma, M. J. D. C., & Nieto, C. (2021) · International Journal of Microbiology and Biotechnology · doi:10.11648/j.ijmb.20210604.11 · Cited by 1
RECURRENT VULVOVAGINAL CANDIDIASIS: CURRENT ISSUES (A REVIEW)
Ratushniak, N., & Sukhanova, A. A. (2022) · World Science · doi:10.31435/rsglobal_ws/28022022/7780 · Cited by 1
Salivary Histatin 5 Level in Women with Vaginal Candidiasis
Şenyuva, İ., Koca, C. G., Çoban, F. K., & Tarhan, Ö. (2022) · International Journal of Clinical Practice · doi:10.1155/2022/5279323 · Cited by 1
Lima, H. G. M., Santos, J. D. S., Markus, G. W. S., Pereira, R. A., & Dias, A. K. (2022) · Research Society and Development · doi:10.33448/rsd-v11i9.29505 · Cited by 1
Treating recurrent vulvovaginal candidiasis
Butler, S. K. (2022) · OBG Management · doi:10.12788/obgm.0238 · Cited by 1
Norouzi, Z., Madani, M., Amjad, L., & Shakib, P. (2023) · Current Drug Therapy · doi:10.2174/1574885518666230223120624 · Cited by 1
de Andrade, A. R. C., Rezende, M. D. S., Portela, F. V. M., Pereira, L. M. G., da Silva, B. N., de Lima-Neto, R. G., Rocha, M. F. G., Sidrim, J. J. C., Castelo‐Branco, D. D. S. C. M., & Cordeiro, R. D. A. (2023) · Biofouling · doi:10.1080/08927014.2023.2256674 · Cited by 1
Liberty, P., Putra, I. B., Jusuf, N. K., & Sari, M. I. (2023) · Acta Medica Bulgarica · doi:10.2478/amb-2023-0039 · Cited by 1
Etiology, Epidemiology and Pathophysiology of Vaginitis
Ismai, M. A., Sharad, N. A., & Al-fahham, A. A. (2024) · INTERNATIONAL JOURNAL OF HEALTH & MEDICAL RESEARCH · doi:10.58806/ijhmr.2024.v3i11n06 · Cited by 1
Ruan, Y., Li, R., Zheng, P., Zhao, S., Wang, Z., Nie, G., & Qian, S. (2025) · ACS Applied Bio Materials · doi:10.1021/acsabm.5c00700 · Cited by 1
Hope in the Treatment of Candida Vaginitis: Ibrexafungerp
Karakoyun, A. S. (2021) · Türk Mikrobiyoloji Cemiyeti Dergisi · doi:10.5222/tmcd.2021.71602 · Cited by 1
Alwaily, E. R., Abood, M. S., & Flaih, M. H. (2022) · International Symposium on Multidisciplinary Studies and Innovative Technologies (ISMSIT) · doi:10.1109/ismsit56059.2022.9932855 · Cited by 1
Dutra, A. M. G., Chiuchetta, G. I. R., & Ecker, A. B. D. S. (2023) · Brazilian Journal of Development · doi:10.34117/bjdv9n1-385 · Cited by 1
Santos, A. S., Zara, A. L. D. S. A., Ataídes, F. S., da Silva, E. G., Freitas, V. A. Q., Costa, C. R., Silva, T. C., & Silva, M. D. R. R. (2020) · Revista de Patologia Tropical / Journal of Tropical Pathology · doi:10.5216/rpt.v49i3.64233 · Cited by 1
Recurrent Candidosis in Clinical Practice of Obstetrician- Gynecologist
Бурьяк, Д. В. (2020) · Репродуктивное здоровье Восточная Европа · doi:10.34883/pi.2020.10.4.003
Modern aspects of recurrent vulvovaginal candidiasis (Literature review)
Sukhanova, A. A., & Ratushniak, N. (2022) · Perinatology and reproductology from research to practice · doi:10.52705/2788-6190-2022-01-6
Candida Vajinitinin Tedavisinde Otesekonazol (VT-1161): Güncel Durum
Karakoyun, A. S., Sucu, M., & İlkit, M. (2022) · Türk Mikrobiyoloji Cemiyeti Dergisi · doi:10.54453/tmcd.2022.36024
Urethritis, Vulvovaginitis, and Cervicitis
Braverman, P. K. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-75608-2.00051-3
Rakhmatulina, M. R. (2023) · Vestnik dermatologii i venerologii · doi:10.25208/vdv11879
Study of the effect of bifonazole concentration on the antifungal activity of vaginal suppositories
Mielnyk, T. V., & Kolycheva, N. L. (2024) · Current issues in pharmacy and medicine science and practice · doi:10.14739/2409-2932.2024.1.294647
Rajivgandhi, G. N., Narayanan, M., Quero, F., Ramachandran, G., Gnanasekaran, C., Palanisamy, B., Chelliah, C. K., & Manoharan, N. (2024) · doi:10.1002/9781394175222.ch12
Microbiome and Reproductive Health
Ijaz, M. U., Hayat, M. F., & Ashraf, A. (2024) · Springer eBooks · doi:10.1007/978-981-97-3790-1_8
Bhat, S., Nagaraj, A., Poojar, B., & Narasimhaswamy, N. (2024) · Reviews in Medical Microbiology · doi:10.1097/mrm.0000000000000394
Candidiasis Treatment: An Evolutionary Journey from Past to Present and a Glimpse into the Future
Bappy, M. N. I., Robin, T. B., & Zinnah, K. M. A. (2024) · Springer eBooks · doi:10.1007/978-981-97-4909-6_3
Sucu, M., Ünal, N., Karakoyun, A. S., Şahin, İ. N., Bingöl, O., Hüner, F., Uzay, F. İ., Ünal, İ., Metin, D. Y., & İlkit, M. (2025) · Journal of Fungi · doi:10.3390/jof11020092 · Cited by 1
Vulvovaginal Candidiasis: Pathophysiology, the Role of Biofilms, and Emerging Therapeutics
Murali, P., Slate, A. J., Kean, R., & Johnston, W. (2025) · Springer series on biofilms · doi:10.1007/978-3-031-93315-8_5
Venchakova, V. V., Oganesyan, E. G., Guseva, A. O., Kovyrshin, S., Rusetskaya, E. V., Marochkovich, O. A., Dolgo-Saburova, Y. V., Богомолова, Т. С., Zhang, F.-M., Meng, Q., et al. (2025) · Clinical Microbiology and Antimicrobial Chemotherapy · doi:10.36488/cmac.2025.1.73-87
Vulvovaginitis refractaria: relevancia clínica de las pruebas de sensibilidad a antifúngicos
Ruiz, S. E., Giraudo, F. J., Peralta, N., & Basso, S. (2025) · Methodo Investigación Aplicada a las Ciencias Biológicas · doi:10.22529/me.2025.10(4)03
Vaginal Microbiota Dynamics as a Key Determinant of Pathogenesis in Fungal Vulvovaginitis
Ruiz-Higareda, A. F., Álvarez-Salas, B. E., García‐Juárez, M., Alanís‐Ríos, S. A., Ríos-López, A. L., Flores-Maldonado, O. E., Heredia-Torres, T. G., Villanueva‐Lozano, H., & Treviño‐Rangel, R. D. J. (2026) · Current Fungal Infection Reports · doi:10.1007/s12281-026-00522-5
Allemailem, K. S. (2026) · Journal of King Saud University - Science · doi:10.25259/jksus_1523_2025
Moreno, X., Cantero-Alvarado, A., Vivas-Parababire, M. G., & Panizo, M. M. (2026) · Investigación Clínica · doi:10.54817/ic.v67n1a04
Jadhav, S. V., Bhalerao, A., & Ansari, Z. N. (2026) · Medical Mycology · doi:10.1093/mmy/myag048
Tsiakalos, A., Papageorgiou, D., Pitiriga, V. C., Vogiatzi, C., Ziakas, P. D., Routsias, I., Dimitroulia, E., & Akinosoglou, K. (2026) · Pathogens · doi:10.3390/pathogens15050538 · Cited by 2
Benhniya, B., Karmil, F. Z., Fahmi, F., Rezzoum, N., Lakhdar, F., & Etahiri, S. (2026) · Algal Research · doi:10.1016/j.algal.2026.104774
Wang, X., Xue, F., Zhang, C., An, R., Ruan, H., Zhu, L., Zhang, L., & Liao, Q. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s599356
Adesiji, Y. O., Eesuola, A. C., Olayiwola, J. F., Ogunniy, T. J., Oladejo, J. M., Aworinde, O., & Ojedele, R. O. (2026) · International Journal of Reproduction Contraception Obstetrics and Gynecology · doi:10.18203/2320-1770.ijrcog20262516
Nanomedicine in the Topical Management of Vulvovaginal Candidiasis: An Overview of In Vivo Data
Lima, A., & das Neves, J. (2026) · Journal of Fungi · doi:10.3390/jof12080562
Management of Recurrent Vaginitis
Powell, A. M., Sobel, J. D., & Muzny, C. A. (2026) · Current Obstetrics and Gynecology Reports · doi:10.1007/s13669-026-00494-w
Self-citation
Metadata
- Authors
- Sobel, J. D., & Sobel, R.
- Affiliations
- Wayne State University (US)
- Thomas Jefferson University Hospital (US)
- Corresponding author
- Sobel, J. D.
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa UK Limited
- Published
- 2018-06-13
- Volume
- 19
- Issue
- 9
- Pages
- 971-977
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- OpenAlex
- W2809133082
- Cited by
- 168
- References
- 56
- Citations by year
- 2026: 11 · 2025: 19 · 2024: 24 · 2023: 39 · 2022: 34 · 2021: 20 · 2020: 13 · 2019: 7 · 2018: 1
- FWCI
- 1.50
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Opinion on Pharmacotherapy (publishedVersion)
- PubMed (publishedVersion)
- Funders
- not funded
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Immunology and Microbiology › Microbiology › Reproductive tract infections research
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Keywords
- vaginal candidiasis, azole resistance, Candida albicans, fluconazole resistance, non-albicans Candida, antifungal resistance, Candida vaginitis
- MeSH terms
- Antifungal Agents, Boric Acids, Candida, Candidiasis, Vulvovaginal, Female, Humans, Microbial Sensitivity Tests, Fluconazole, Drug Resistance, Fungal, 14-alpha Demethylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
